(Q38376598)

2 September 2017

1 reference

title

Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme (English)

1 reference

2 September 2017

1 reference

1 reference

1 reference

Alia Hdeib

1

1 reference

2 September 2017

Andrew Edward Sloan

series ordinal

2

1 reference

2 September 2017

language of work or name

1 reference

1 January 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

4

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

63-69

1 reference

CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

2 September 2017

cites work

1 reference

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

21 January 2018

1 reference

An extent of resection threshold for newly diagnosed glioblastomas

21 January 2018

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

Targeted therapy for brain tumours

21 January 2018

1 reference

Convection-enhanced delivery of macromolecules in the brain

21 January 2018

1 reference

Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas

21 January 2018

1 reference

Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas

21 January 2018

1 reference

Convection enhanced delivery of macromolecules for brain tumors

21 January 2018

1 reference

Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial

21 January 2018

1 reference

Functional nanoparticles in targeting glioma diagnosis and therapies

21 January 2018

1 reference

Vaccines for glioblastoma and high-grade glioma

21 January 2018

1 reference

A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer

21 January 2018

1 reference

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

21 January 2018

1 reference

CD83 expression on dendritic cells and T cells: correlation with effective immune responses

21 January 2018

1 reference

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

21 January 2018

1 reference

Mechanisms of immunomodulation in human glioblastoma.

21 January 2018

1 reference

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

21 January 2018

1 reference

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue

21 January 2018

1 reference

Immunotherapy with tumor vaccines for the treatment of malignant gliomas

21 January 2018

1 reference

Technology evaluation: DCVax, Northwest Biotherapeutics.

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6093019

Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients

5 November 2018

1 reference

DCVax-Brain and DC vaccines in the treatment of GBM

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25768330

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2217/CNS.14.54

1 reference

2 September 2017

0 references

1 reference